Response to Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"

J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz135. doi: 10.1210/clinem/dgz135.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Hypoglycemic Agents / adverse effects
  • Pioglitazone*
  • Sulfonylurea Compounds* / adverse effects

Substances

  • Hypoglycemic Agents
  • Sulfonylurea Compounds
  • Pioglitazone